Litigation Details for Pharmacyclics LLC v. Alvogen Pine Brook, LLC (D. Del. 2020)
✉ Email this page to a colleague
Pharmacyclics LLC v. Alvogen Pine Brook, LLC (D. Del. 2020)
| Docket | ⤷ Sign Up | Date Filed | 2020-03-20 |
| Court | District Court, D. Delaware | Date Terminated | 2021-04-13 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | Defendant | Referred To | |
| Parties | JANSSEN BIOTECH, INC. | ||
| Patents | 10,010,507; 10,213,386; 10,463,668; 10,478,439; 7,514,444; 8,008,309; 8,476,284; 8,497,277; 8,501,751; 8,697,711; 8,703,780; 8,735,403; 8,754,090; 8,754,091; 8,952,015; 8,987,421; 8,999,999; 9,125,889; 9,296,753; 9,540,382; 9,655,857; 9,713,617; 9,725,455; 9,795,604 | ||
| Attorneys | Jennifer Liu | ||
| Firms | Morris, Nichols, Arsht & Tunnell | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Pharmacyclics LLC v. Alvogen Pine Brook, LLC
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Pharmacyclics LLC v. Alvogen Pine Brook, LLC (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2020-03-20 | 1 | Complaint | prior to the expiration of U.S. Patent No. 10,478,439 (“the ’439 Patent”). Zydus has submitted amendments…. This action for patent infringement, brought pursuant to the patent laws of the United States…action for infringement of the ’439 Patent. 3. Other patent infringement actions relating to…46. This civil action for patent infringement arises under the patent laws of the United States, including… THE ASSERTED PATENT 102. The ’439 Patent, entitled “Use of Inhibitors of | External link to document |
| 2020-04-27 | 19 | Complaint - Amended | expiration of the ’439 Patent and U.S. Patent No. 10,463,668 (“the ’668 Patent”). Alvogen- Natco has …. This action for patent infringement, brought pursuant to the patent laws of the United States…prior to the expiration of U.S. Patent No. 10,478,439 (“the ’439 Patent”). Zydus has submitted amendments…infringement of the ’439 and ’668 Patents. 3. Other patent infringement actions relating to…The ’439 Patent is listed in the Orange Book for IMBRUVICA®. 12. The ’668 Patent is listed | External link to document |
| 2020-04-27 | 20 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,463,668 . (Blumenfeld, Jack…2020 13 April 2021 1:20-cv-00403 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2020-10-14 | 52 | Complaint - Amended | ” Curr HematolMalig Rep , 8 ( 1 ): 10,010,507 B1 * 7/2018 Chong A61K 9… ’439 Patent, the ’634 Patent, U.S. Patent No. 10,463,668 (“the ’668 Patent”), and U.S. Patent No. 10,695,350…of U.S. Patent No. 10,478,439 (“the ’439 Patent”), U.S. Patent No. 10,653,696 (“the ’696 Patent”), and… date of the ’439 Patent, ’668 Patent, ’634 Patent, or ’350 Patent or any later …exclusivity for the ’439 Patent, ’668 Patent, ’634 Patent, or ’350 Patent including any extensions | External link to document |
| 2020-10-26 | 59 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,463,668 B2 ;10,653,696 B2 …2020 13 April 2021 1:20-cv-00403 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
